非高密度脂蛋白胆固醇作为降脂治疗目标的意义  

Meaning of targeting non-high-density lipoprotein cholesterol in lipid-lowering therapy

作　　者：杨阳[1] 彭道泉[1] Yang Yang;Peng Daoquan(Department of Second Xiangya Hospital of Central South University,Changsha 410011,China)

机构地区：[1]中南大学湘雅二医院心内科,长沙410011

出　　处：《中华检验医学杂志》2021年第7期569-573,共5页Chinese Journal of Laboratory Medicine

基　　金：国家自然科学基金(81870336,81670426);湖南省自然科学基金(2018JJ2596);湖南省自然科学基金(2018JJ1045)。

摘　　要：低密度脂蛋白胆固醇(LDL-C)被推荐为冠心病患者降脂治疗的主要治疗目标。然而,即使通过积极的降低LDL-C治疗,患者仍然存在显著残留心血管事件风险。非高密度脂蛋白胆固醇(HDL-C)包含所有致动脉粥样硬化脂蛋白。非HDL-C在预测心血管事件方面优于LDL-C,并且比LDL-C及其他血脂指标具有更多显著优势。该文主要讨论非HDL-C的含义和检验优势、预测价值、目标值及相关指南推荐等。Low-density lipoprotein cholesterol(LDL-C)has been recommended as the primary treatment target on lipid management in coronary heart disease(CHD)patients for several decades.However,even by aggressive LDL-C lowering treatment,patients still present a significant residual risk of major adverse cardiovascular events.Non-high-density lipoprotein cholesterol(non-HDL-C)contained all the atherogenic lipoproteins.Non-HDL-C is superior to LDL-C for the prediction of cardiovascular events and has many other compelling advantages over LDL-C and other traditional lipid parameters.This review mainly discusses the definition and test advantages of non-HDL-C,the predictive value of non-HDL-C,recommended value of non-HDL-C goals,and related guideline recommendations of non-HDL-C.

关 键 词：冠状动脉疾病 低密度脂蛋白胆固醇 非高密度脂蛋白胆固醇 

分 类 号：R541.4[医药卫生—心血管疾病]